April 2015

While ibrutinib is a relatively new option in the treatment of B-cell NHL, it has convincing antitumor activity as a single agent in a wide variety of B-cell lymphoma subtypes and is a viable therapeutic option for patients.

Common AEs associated with brentuximab vedotin, such as peripheral neuropathy and neutropenia, are often manageable with modifications to dose and schedule.

Various isoforms of PI3Ks exist, including the delta (δ) and gamma (γ) isoforms, which show a preferential expression in cells of the immune system.